SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SAN DIEGO, Nov. 02, 2017 -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that three abstracts detailing preclinical data have been selected for presentation at the American Society of Hematology (ASH) Annual Meeting. Data will be presented at the 2017 ASH Annual Meeting in Atlanta on December 9th and 10th. Abstracts are currently available online at http://www.hematology.org/Annual-Meeting/Abstracts/.
The following abstracts will be presented:
Presentation Title: The Application of ‘Drug-Reversible’ CAR-T Cells Directed Against Recipient Hematopoietic Cells As a Selective Conditioning Strategy for Stem Cell Transplantation
Abstract Number: 1893
Date and Time: 5:30 p.m.-7:30 p.m., Saturday, December 9, 2017
Location: Georgia World Congress Center, Building A, Level 1, Hall A2
Presentation Title: Production of Universal Anti-BCMA CAR-T Cells with Reduced Alloreactivity, but Potent Effector Function for the Treatment of Multiple Myeloma
Abstract Number: 503
Date and Time: 5:30 p.m., Sunday, December 10, 2017
Location: Georgia World Congress Center, Building B, Level 3, B308-B309
Presentation Title: B-Cell Maturation Antigen (BCMA)-Specific, Centyrin™-Based, PiggyBac™-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors
Abstract Number: 3068
Date and Time: 6:00 p.m.-8:00 p.m., Sunday, December 10, 2017
Location: Georgia World Congress Center, Building A, Level 1, Hall A2
About Poseida Therapeutics, Inc.
Poseida Therapeutics is translating best-in-class gene therapy technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for cancer, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida’s lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene therapy technologies, including the piggyBac™ DNA Modification System, XTN™ TALEN and NextGEN™ CRISPR site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com.
Corporate Communications Contact:
Jason Spark
Canale Communications
619-849-6005
[email protected]
